# US 2014/0154314 A1 · Delayed-release formulation for reducing the frequency of urination and method of use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0154314 A1
- Document ID: US20140154314A1
- Status: Published application
- Kind: A1
- Application number: 14/175,183
- Filed: 2014-02-07
- Published: 2014-06-05
- Earliest claimed: 2010-07-08
- Assignees: Wellesley Pharmaceuticals, LLC
- Applicants: Wellesley Pharmaceuticals, LLC
- Inventors: David A. DILL
- Web page: https://patentgrep.com/patent/US20140154314A1

## CPC

- A61K 31/618: having the carboxyl group in position 1 esterified, e.g. salsalate
- A61K 9/0004: {Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas}
- A61K 9/2846: {Poly(meth)acrylates}
- A61K 9/2866: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 9/288: {Compounds of unknown constitution, e.g. material from plants or animals (oils, fats, waxes, shellac A61K9/282)}
- A61K 9/4891: {Coated capsules; Multilayered drug free capsule shells (with drug coating for immediate release A61K9/4808; osmotic devices A61K9/0004)}
- A61K 31/167: having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
- A61K 31/19: Carboxylic acids, e.g. valproic acid (salicylic acid A61K31/60)
- A61K 31/192: having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid {(cannabinoids A61K31/658)}
- A61K 31/216: of acids having aromatic rings, e.g. benactizyne, clofibrate
- A61K 31/4025: not condensed and containing further heterocyclic rings, e.g. cromakalim
- A61K 31/439: the ring forming part of a bridged ring system, e.g. quinuclidine (8-azabicyclo [3.2.1] octanes A61K31/46)
- A61K 31/4709: Non-condensed quinolines and containing further heterocyclic rings
- A61K 31/60: Salicylic acid; Derivatives thereof
- A61K 31/616: by carboxylic acids, e.g. acetylsalicylic acid
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 7/12: Antidiuretics, e.g. drugs for diabetes insipidus (ADH A61P5/10)
- A61P 13/00: Drugs for disorders of the urinary system
- A61P 13/02: of urine or of the urinary tract, e.g. urine acidifiers
- A61P 13/10: of the bladder
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Methods and compositions for reducing the frequency of urination are disclosed. One method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising an analgesic agent formulated in a delayed-release formulation. Another method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising multiple active ingredients. Yet another method comprises administering to a subject in need thereof an effective amount of a diuretic followed with another administration of a pharmaceutical composition comprising an analgesic agent.

## Claims

### Claim at position 1

1-30. (canceled)

### Claim 31

A method for reducing the frequency of urination, comprising:
administering to a subject who desires to reduce the frequency of urination an effective amount of a pharmaceutical composition comprising acetaminophen formulated in delayed-release formulation,
wherein said acetaminophen is administered at a daily dose of 5 mg to 2000 mg.

### Claim 32 (depends on 31)

The method of claim 31, wherein said acetaminophen is administered at a daily dose of 100 mg to 500 mg.

### Claim 33 (depends on 31)

The method of claim 31, wherein said acetaminophen is administered at a daily dose of 500 mg to 2000 mg.

### Claim 34 (depends on 31)

The method of claim 31, wherein said acetaminophen is administered at a daily dose of 50 mg to 1600 mg.

### Claim 35 (depends on 31)

The method of claim 31, wherein said pharmaceutical composition further comprises one or more antimuscarinic agents.

### Claim 36 (depends on 31)

The method of claim 31, wherein said pharmaceutical composition further comprises one or more antidiuretics.

### Claim 37 (depends on 31)

The method of claim 31, wherein said pharmaceutical composition further comprises one or more spasmolytics.

### Claim 38 (depends on 31)

The method of claim 31, wherein said delayed-release formulation comprises a material selected from the group consisting of hydroxypropyl methylcellulose, methylcellulose, methyl hydroxyethylcellulose, hydroxypropylcellulose, carboxymethylcellulose, acrylate copolymers, polyethylene glycols, polyvinylpyrrolidone, methacrylic acid copolymer, cellulose acetate phthalate, hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate succinate, polyvinyl acetate phthalate, shellac, and ethylcellulose.

### Claim 39 (depends on 31)

The method of claim 31, wherein said delayed-release formulation comprises glyceryl monostearate or glyceryl distearate.

### Claim 40 (depends on 31)

The method of claim 31, wherein said delayed-release formulation comprises a water insoluble capsule body closed at one end with an insoluble, but permeable and swellable hydrogel plug, wherein said plug comprises a material selected from the group consisting of polymethacrylates, erodible compressed polymers, congealed melted polymer and enzymatically controlled erodible polymers.

### Claim 41 (depends on 31)

The method of claim 31, wherein said delayed-release formulation comprises an enteric coating.

### Claim 42 (depends on 31)

The method of claim 31, wherein said pharmaceutical composition further comprises one or more analgesic agents selected from the group consisting of aspirin, ibuprofen, naproxen, naproxen sodium, indomethacin and nabumetone.

### Claim 43 (depends on 31)

The method of claim 31, wherein said pharmaceutical composition is administered orally.

### Claim 44 (depends on 31)

The method of claim 31, wherein said pharmaceutical composition is formulated for the oral administration.

### Claim 45

A method for reducing the frequency of urination, comprising:
administering to a subject who desires to reduce the frequency of urination an effective amount of a pharmaceutical composition comprising acetaminophen formulated for immediate release,
wherein said acetaminophen is administered at a daily dose of 10 mg to 2000 mg.

### Claim 46 (depends on 45)

The method of claim 45, wherein said acetaminophen is administered at a daily dose of 100 mg to 500 mg.

### Claim 47 (depends on 45)

The method of claim 45, wherein said acetaminophen is administered at a daily dose of 250 mg to 500 mg.

### Claim 48 (depends on 45)

The method of claim 45, wherein said acetaminophen is administered at a daily dose of 250 mg to 1000 mg.

### Claim 49 (depends on 45)

The method of claim 45, wherein said pharmaceutical composition further comprises one or more antimuscarinic agents selected from the group consisting of oxybutynin, solifenacin, darifenacin and atropine.

### Claim 50 (depends on 45)

The method of claim 45, wherein said pharmaceutical composition further comprises one or more antidiuretics.

### Claim 51 (depends on 45)

The method of claim 45, wherein said pharmaceutical composition further comprises one or more spasmolytics.

### Claim 52 (depends on 45)

The method of claim 45, wherein said pharmaceutical composition further comprises one or more analgesic agent selected from the group consisting of aspirin, ibuprofen, naproxen, naproxen sodium, indomethacin and nabumetone.

### Claim 53

A method for reducing the frequency of urination, comprising:
administering to a subject who desires to reduce the frequency of urination an effective amount of a pharmaceutical composition comprising acetaminophen formulated in delayed-release formulation having an immediate-release component and a delayed-release component,
wherein said acetaminophen is administered at a daily dose of 5 mg to 2000 mg.

### Claim 54 (depends on 53)

The method of claim 53, wherein said s delayed-release component may also be an extended release component that is delayed.

### Claim 55 (depends on 53)

The method of claim 53, wherein said pharmaceutical composition further comprises one or more antimuscarinic agents in said immediate-release component, or said delayed-release component, or both components.

### Claim 56 (depends on 53)

The method of claim 53, wherein said pharmaceutical composition further comprises one or more antidiuretics in said immediate-release component, or said delayed-release component, or both components.

### Claim 57 (depends on 53)

The method of claim 53, wherein said pharmaceutical composition further comprises one or more spasmolytics in said immediate-release component, or said delayed-release component, or both components.

### Claim 58 (depends on 53)

The method of claim 53, wherein said pharmaceutical composition further comprises one or more analgesic agents in said immediate-release component, or said delayed-release component, or both components,
wherein said one or more analgesic agents are selected from the group consisting of aspirin, ibuprofen, naproxen, naproxen sodium, indomethacin and nabumetone.

### Claim 59 (depends on 53)

The method of claim 53, wherein said pharmaceutical composition is administered orally.

### Claim 60 (depends on 53)

The method of claim 53, wherein said pharmaceutical composition is formulated for the oral administration.

### Claim 61 (depends on 53)

The method of claim 53, wherein said pharmaceutical composition further comprises one or more analgesic agents in said immediate-release component, extended, or said delayed-release component, or any combination of components.
